Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques

(2021) Ramon Roozendaal et al.   Nature Communications

Emerging small and large molecule therapeutics for respiratory syncytial virus

(2020) Harrison C. Bergeron et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Characterization of human respiratory syncytial virus (RSV) isolated from HIV‐exposed‐uninfected and HIV‐unexposed infants in South Africa during 2015‐2017

(2020) Hui Liu et al.   Influenza and Other Respiratory Viruses

Monoclonal Antibodies for Prevention and Treatment of COVID-19

(2020) Mary Marovich et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Recent successes in therapeutics for Ebola virus disease: no time for complacency

(2020) Patrick L Iversen et al.   LANCET INFECTIOUS DISEASES

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

(2020) M. Pamela Griffin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose finding for new vaccines: The role for immunostimulation/immunodynamic modelling

(2019) Sophie J. Rhodes et al.   JOURNAL OF THEORETICAL BIOLOGY

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein

(2019) Aimin Tang et al.   Nature Communications

Safety, Tolerability, and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

(2018) Joseph B. Domachowske et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field

(2018) Prasad S. Kulkarni et al.   VIRAL IMMUNOLOGY

Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset

(2018) Vicente Mas et al.   VACCINE

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

(2017) Qing Zhu et al.   Science Translational Medicine

Antibody therapies for the prevention and treatment of viral infections

(2017) Georgina Salazar et al.   npj Vaccines

Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B

(2017) Anne M. Hause et al.   PLoS One

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults

(2016) M. Pamela Griffin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

(2015) Katherine L O'Brien et al.   LANCET INFECTIOUS DISEASES

Respiratory Syncytial Virus Surveillance in the United States, 2007–2012

(2014) Catherine Balderston McGuiness et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

(2014)   PEDIATRICS

Correlates of Protection Induced by Vaccination

(2010) S. A. Plotkin   Clinical and Vaccine Immunology